A Phase I, Open Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk, Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed LymphomaPeter Martin, Leandro Cerchietti, Ildefonso Ismael Rodriguez Rivera et al.|Blood|2017Cited by 8